Teva Pharmaceuticals
TEVA
798 hedge funds and large institutions have $26.2B invested in Teva Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 70 funds opening new positions, 269 increasing their positions, 325 reducing their positions, and 74 closing their positions.
4% less call options, than puts
Call options by funds: $595M | Put options by funds: $620M
5% less first-time investments, than exits
New positions opened: 70 | Existing positions closed: 74
2% less funds holding
Funds holding: 813 → 798 (-15)
2.2% less ownership
Funds ownership: 58.28% → 56.08% (-2.2%)
13% less capital invested
Capital invested by funds: $29.9B → $26.2B (-$3.77B)
15% less funds holding in top 10
Funds holding in top 10: 41 → 35 (-6)
17% less repeat investments, than reductions
Existing positions increased: 269 | Existing positions reduced: 325
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$310M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$295M |
| 3 |
Barrow, Hanley, Mewhinney & Strauss
Dallas,
Texas
|
+$202M |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
+$188M |
| 5 |
JP Morgan Chase
New York
|
+$179M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$420M |
| 2 |
PC
PointState Capital
New York
|
-$309M |
| 3 |
HCM
Highfields Capital Management
Boston,
Massachusetts
|
-$280M |
| 4 |
IC
Institutional Capital
Chicago,
Illinois
|
-$217M |
| 5 |
MIFH
Migdal Insurance & Financial Holdings
Petach Tikva,
Israel
|
-$193M |
TEVA Hedge Fund Activity: Q3 2016 in Review
798 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q3 2016, worth a combined $26.2B — down 13% from $29.9B a quarter earlier.
Sellers outnumbered buyers: 74 funds closed out of TEVA and 70 opened new positions — a net loss of 4 holders — while 325 trimmed existing stakes and 269 added.
The largest buyer was Morgan Stanley, adding an estimated $310M. The largest seller was Viking Global Investors, cutting an estimated $420M.
- 798 institutional investors held Teva Pharmaceuticals (TEVA) as of Q3 2016, down from 813 in Q2 2016.
- Funds reported $26.2B of Teva Pharmaceuticals stock for Q3 2016, down 13% quarter-over-quarter.
- 70 funds opened new Teva Pharmaceuticals positions in Q3 2016 and 74 closed out, a net change of -4 holders.
- The largest Teva Pharmaceuticals buyer in Q3 2016 was Morgan Stanley, an estimated $310M added.
- The largest Teva Pharmaceuticals seller in Q3 2016 was Viking Global Investors, an estimated $420M sold.
Based on aggregated 13F filings for Q3 2016.